Corvus Pharmaceuticals (CRVS) Return on Equity (2016 - 2026)

Corvus Pharmaceuticals' Return on Equity history runs 11 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Equity rose 1.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (up 1.0% YoY), while the FY2025 annual figure was 0.0%, up 1.0% from the prior year.
• Return on Equity was 0.0% for Q1 2026 at Corvus Pharmaceuticals, down from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q3 2025 to a low of 0.03% in Q4 2024.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.01% in 2023.
• The sharpest annual moves came in 2024 and 2025: Return on Equity fell 2 bps in 2024, then gained 2 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then grew by 3 bps to 0.01% in 2023, then tumbled by 401 bps to 0.03% in 2024, then surged by 92 bps to 0.0% in 2025, then slumped by 39 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.